Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 7/20 | 0.81 |
| ▸ | FNTA | P49354 | 12/20 | 0.54 |
| ▸ | FNTB | P49356 | 10/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83423 | 0.90 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL254662 | 0.90 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL14387716 | 0.90 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL12640194 | 0.87 | BTN3A1 (0.93) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL2785835 | 0.80 | BTN3A1 (0.75) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL23455692 | 0.79 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL570052 | 0.79 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL27728718 | 0.78 | BTN3A1 (0.73) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL27728719 | 0.78 | BTN3A1 (0.73) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL27708274 | 0.78 | BTN3A1 (0.73) | BTN3A1FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112054-A1 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells | BIOAGENCY AG (DE) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112054-A1 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells | CD4, GZMB, PITPNB | BTN3A1 139/4885FNTA 1011/4885FNTB 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.